All Stories

  1. Size exclusion chromatography provides evidence for a possible role of L-histidine in the organ availability of the carcinogen Ni2+
  2. Tailoring LC approaches to address the chemical biology of toxic metals in humans
  3. Tailoring LC-based metallomics methods to disentangle the bioinorganic chemistry of toxic mercury and cadmium species at the blood-organ nexus
  4. Linking dynamic bioinorganic chemistry processes of toxic metals in the bloodstream to establish their exposure-response relationship in humans
  5. Degradation of the Vaccine Additive Thimerosal by L-Glutathione and L-Cysteine at Physiological pH
  6. Chemical Hazard Assessment of Vanadium–Vanadium Flow Battery Electrolytes in Failure Mode
  7. Phenylmercuric acetate is degraded by L-cysteine at near physiological conditions
  8. The metal(loid)s’ dilemma. What's the next step for a new era of inorganic molecules in medicine?
  9. Liquid chromatography-based metallomics and transmission electron microscopy reveal gold nanoparticle surface treatment with vicinal dithiols to abolish protein corona formation
  10. HPLC separation of Hg2+, MeHg+, thimerosal and phenylmercuric acetate
  11. The biochemical fate of three organomercurials was investigated using ESI-MS
  12. Translational toxicology of metal(loid) species: linking their bioinorganic chemistry in the bloodstream to organ damage onset
  13. We investigated how N-acetylcysteine modulates the metabolism of Hg2+ and CH3Hg+
  14. We directly observed the L-cysteine mediated mobilization of Hg2+ and Cd2+ from HSA
  15. Structural Characterization of Toxicologically Relevant Cd2+-L-Cysteine Complexes
  16. Integrative Metallomics Studies of Toxic Metal(loid) Substances at the Blood Plasma–Red Blood Cell–Organ/Tumor Nexus
  17. Physiologically relevant hCys concentrations mobilize MeHg from rabbit serum albumin to form MeHg–hCys complexes
  18. Quantification of human plasma metalloproteins in multiple sclerosis, ischemic stroke and healthy controls reveals an association of haptoglobin-hemoglobin complexes with age
  19. Toxic Metal Species and ‘Endogenous’ Metalloproteins at the Blood–Organ Interface: Analytical and Bioinorganic Aspects
  20. Linking molecular targets of Cd in the bloodstream to organ-based adverse health effects
  21. Results into the metabolism of metal-based anticancer drugs in blood plasma are presented
  22. Sample preparation of blood plasma enables baseline separation of iron metalloproteins by SEC-GFAAS
  23. SEC hyphenated to a multielement-specific detector unravels the degradation pathway of a bimetallic anticancer complex in human plasma
  24. Identification of a haptoglobin-hemoglobin complex in human blood plasma
  25. The cisplatin/serum albumin system: A reappraisal
  26. Development of an analytical method to quantify EDTA and DTPA in real WTP effluents.
  27. Organ damage by toxic metals is critically determined by the bloodstream
  28. Improving the safety of metal-based drugs by tuning their metabolism with chemoprotective agents
  29. Environmentally relevant concentrations of aminopolycarboxylate chelating agents mobilize Cd from humic acid
  30. Remarkable differences in the biochemical fate of Cd2+, Hg2+, CH3Hg+ and thimerosal in red blood cell lysate
  31. Selenium-mediated arsenic excretion in mammals: a synchrotron-based study of whole-body distribution and tissue-specific chemistry
  32. Probing the interaction of bisintercalating (2,2′:6′,2″-terpyridine)platinum(II) complexes with glutathione and rabbit plasma
  33. Chemical basis for the detoxification of cisplatin-derived hydrolysis products by sodium thiosulfate
  34. Physiologically relevant plasma d , l -homocysteine concentrations mobilize Cd from human serum albumin
  35. Glutathione effectively modulates the metabolism of cisplatin
  36. Tuning the metabolism of the anticancer drug cisplatin with chemoprotective agents to improve its safety and efficacy
  37. Transforming the anticancer drug cisplatin into a better drug
  38. Reducing the toxicity of the anticancer drug cisplatin
  39. Mitigating Cd bioaccummulation in human tissues